Drug Profile
Peptide YY - RELIEF THERAPEUTICS Holding
Latest Information Update: 18 Sep 2023
Price :
$50
*
At a glance
- Originator mondoBIOTECH
- Developer RELIEF THERAPEUTICS Holding
- Class Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Hepatitis B
Most Recent Events
- 18 Sep 2023 Discontinued - Preclinical for Hepatitis B in Switzerland (unspecified route) (RELIEF THERAPEUTICS pipeline, September 2023)
- 28 Apr 2018 No recent reports of development identified for preclinical development in Hepatitis-B in Switzerland
- 20 Sep 2016 Peptide YY - RELIEF THERAPEUTICS Holding is available for licensing as of 20 Sep 2016. http://www.relieftherapeutics.com/further-opportunities/